Business Context and Reporting Period
This Form 8-K was filed by MedTech Acquisition Corporation, not Trisalus Life Sciences, Inc., and reports events occurring on November 1, 2022. MedTech is a Delaware special purpose acquisition company with securities listed on Nasdaq under MTACU, MTAC, and MTACW.
Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes Versus Prior Period
The filing does not report financial or operational changes versus a prior comparable period. It announces that a special meeting of stockholders will be held in lieu of the 2022 annual meeting.
Guidance, Outlook, Risks, and Unusual Items
- The special meeting is scheduled for December 7, 2022. The definitive proxy statement will provide the meeting time and location.
- Stockholders seeking to submit business or nominate director candidates were required to deliver proposals or nominations to the company’s principal executive offices by November 7, 2022.
- Any proposals or nominations must comply with Delaware law, SEC rules, and the company’s bylaws.
Important Facts to Verify
- Verify the filing entity: the source document identifies MedTech Acquisition Corporation, while the request metadata identifies Trisalus Life Sciences, Inc.
- Review the definitive proxy statement for the meeting agenda, transaction-related matters, voting requirements, and meeting logistics.
- Confirm whether any subsequent filings changed the meeting date, nomination deadline, or proposed corporate actions.